- Home
- EDRY vs NRSN Comparison
EDRY vs NRSN Comparison
Compare EDRY & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- NRSN
- Stock Information
- Founded
- EDRY 2018
- NRSN 2017
- Country
- EDRY Greece
- NRSN Israel
- Employees
- EDRY N/A
- NRSN N/A
- Industry
- EDRY Marine Transportation
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- NRSN Health Care
- Exchange
- EDRY Nasdaq
- NRSN Nasdaq
- Market Cap
- EDRY 35.4M
- NRSN 29.8M
- IPO Year
- EDRY N/A
- NRSN 2021
- Fundamental
- Price
- EDRY $12.53
- NRSN $0.93
- Analyst Decision
- EDRY
- NRSN Buy
- Analyst Count
- EDRY 0
- NRSN 2
- Target Price
- EDRY N/A
- NRSN $14.00
- AVG Volume (30 Days)
- EDRY 3.0K
- NRSN 197.1K
- Earning Date
- EDRY 11-10-2025
- NRSN 12-17-2025
- Dividend Yield
- EDRY N/A
- NRSN N/A
- EPS Growth
- EDRY N/A
- NRSN N/A
- EPS
- EDRY N/A
- NRSN N/A
- Revenue
- EDRY $49,707,775.00
- NRSN N/A
- Revenue This Year
- EDRY N/A
- NRSN N/A
- Revenue Next Year
- EDRY $20.65
- NRSN N/A
- P/E Ratio
- EDRY N/A
- NRSN N/A
- Revenue Growth
- EDRY N/A
- NRSN N/A
- 52 Week Low
- EDRY $7.60
- NRSN $0.80
- 52 Week High
- EDRY $16.20
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- EDRY 60.29
- NRSN 30.12
- Support Level
- EDRY $12.09
- NRSN $1.02
- Resistance Level
- EDRY $13.00
- NRSN $1.14
- Average True Range (ATR)
- EDRY 0.27
- NRSN 0.07
- MACD
- EDRY 0.04
- NRSN -0.02
- Stochastic Oscillator
- EDRY 100.00
- NRSN 10.13
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.